bioengineering

(redirected from bioengineered)
Also found in: Dictionary, Thesaurus, Encyclopedia.

engineering

 [en″jĭ-nēr´ing]
the application of scientific and mathematical principles to useful ends, such as in the development of mechanical devices, systems, or processes.
biomedical engineering bioengineering.

bi·o·med·i·cal en·gi·neer·ing

application of engineering principles to obtain solutions to biomedical problems.

bioengineering

(bī′ō-ĕn′jə-nîr′ĭng)
n.
1. The application of engineering principles and techniques to the field of biology, especially biomedicine, as in the development of prostheses, biomaterials, and medical devices and instruments. Also called biomedical engineering.
2. Genetic engineering.

bioengineering

(1) The science of developing and manufacturing artificial replacements for organs, limbs and tissues.
(2) A branch of civil engineering based on use of living plants for erosion control and landscape restoration.

bioengineering

The science of developing and manufacturing artificial replacements for organs, limbs and tissues. See Biomaterial.

bioengineering

See BIOLOGICAL ENGINEERING

bioengineering

  1. the application of technological processes to the biological synthesis of compounds of economic and medical importance. See GENETIC ENGINEERING.
  2. the creation of artifical replacements for body parts.
References in periodicals archive ?
reports the successful orthotopic transplantation of a bioengineered lacrimal gland germ into an adult extra-orbital lacrimal gland defect model mouse, which mimics the corneal epithelial damage caused by lacrimal gland dysfunction.
Ronnie Cummins, the national director of the Organic Consumers Association, disagrees, saying that allergies are just one of the possible negative health effects of bioengineered food.
Despite the promise of bioengineered corneal surface transplants, a few problems still must be worked-out, Isseroff and Schwab acknowledged in a commentary accompanying the report from Tsai's group.
Highlights - The global market for bioengineered protein drugs was valued at $151.
a pioneer in regenerative medicine, today announced the presentation of interim, first-in-human data from an ongoing, multi-center study in Poland, evaluating the company's investigational bioengineered blood vessel in hemodialysis patients with End-Stage Renal Disease (ESRD).
today announced the accomplishment of significant milestones in the clinical development of its innovative bioengineered blood vessel technology - the first off-the-shelf, human-derived, artificial blood vessels.
and stem cell research, scientists involved with the MUSC Bioengineered Kidney Project are testing the possibility of creating a new kidney from a patient's cells.
To support the survival of cells growing deep inside bioengineered replacement tissues, researchers have devised a method to create microchannels that allow blood vessels to grow into the scaffold, bringing critical nutrients to the cells, as reported in the September 2006 issue (Volume 12, Number 9) of Tissue Engineering, a peer-reviewed journal published by Mary Ann Liebert, Inc.
NASDAQ: BSMD) ("BioSphere"), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations, today announced the Company's sponsorship of a symposium highlighting the technical and clinical aspects of its HepaSphere(TM) Microspheres in the treatment of primary and metastatic liver cancer.
Nasdaq:BSMD), the medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, announced today that it will hold its quarterly conference call to discuss second quarter 2006 results on July 27, 2006, at 11:00 a.
NASDAQ: BSMD), a medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization announced today that Richard Faleschini, President and Chief Executive Officer will be presenting an overview of the Company at the C.
NASDAQ: BSMD), a medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, today announced its participation in a Phase II, single-arm clinical study to treat patients with primary liver cancer.